PMID- 16996205
OWN - NLM
STAT- MEDLINE
DCOM- 20070516
LR  - 20101118
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 248
IP  - 2
DP  - 2007 Apr 18
TI  - Insulin-like growth factor-1 receptor and ligand targeting in head and neck 
      squamous cell carcinoma.
PG  - 269-79
AB  - IGF-1 receptor (IGF-1R) signaling is associated with increased tumorigenesis of 
      epithelial cancers. In light of recent epidemiological studies correlating high 
      circulating levels of IGF-1 with increased risk of second primary tumors (SPTs) 
      of the head and neck, we examined IGF system and epidermal growth factor receptor 
      (EGFR) expression in human head and neck squamous cell carcinoma (HNSCC) matched 
      pairs and a cross-section of HNSCC cell lines. Employing the latter, we 
      demonstrated that IGF-1 stimulated S-phase transition in a PI 3-K/Akt and 
      Erk-dependent manner in 5 of 8 cell lines, with Erk activation being dependent 
      upon EGFR kinase activity. IGF-1 stimulated thymidine incorporation was inhibited 
      by treatment with IGFBP-3, the IGF-1R tyrosine kinase inhibitor NVP-AEW541, or 
      the EGFR tyrosine kinase inhibitor AG1478. Combining IGFBP-3 with NVP-AEW541 or 
      AG1478 abrogated IGF-1 responses at 10-fold lower doses than either compound 
      alone. These results demonstrate the potential for co-targeting the IGF system 
      and EGFR in HNSCC.
FAU - Slomiany, Mark G
AU  - Slomiany MG
AD  - Department of Cell and Molecular Pharmacology and Experimental Therapeutics and 
      Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 
      29425, USA.
FAU - Black, Leigh Ann
AU  - Black LA
FAU - Kibbey, Megan M
AU  - Kibbey MM
FAU - Tingler, Melissa A
AU  - Tingler MA
FAU - Day, Terry A
AU  - Day TA
FAU - Rosenzweig, Steven A
AU  - Rosenzweig SA
LA  - eng
PT  - Journal Article
DEP - 20060922
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Insulin-Like Growth Factor Binding Proteins)
RN  - 0 (Ligands)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Carcinoma, Squamous Cell/*metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Head and Neck Neoplasms/*metabolism
MH  - Humans
MH  - Immunoblotting
MH  - Insulin-Like Growth Factor Binding Proteins/*metabolism
MH  - Ligands
MH  - Phosphatidylinositol 3-Kinases/drug effects/metabolism
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Proto-Oncogene Proteins c-akt/drug effects/metabolism
MH  - Receptor, IGF Type 1/*metabolism
EDAT- 2006/09/26 09:00
MHDA- 2007/05/17 09:00
CRDT- 2006/09/26 09:00
PHST- 2006/05/30 00:00 [received]
PHST- 2006/07/31 00:00 [revised]
PHST- 2006/08/02 00:00 [accepted]
PHST- 2006/09/26 09:00 [pubmed]
PHST- 2007/05/17 09:00 [medline]
PHST- 2006/09/26 09:00 [entrez]
AID - S0304-3835(06)00497-6 [pii]
AID - 10.1016/j.canlet.2006.08.004 [doi]
PST - ppublish
SO  - Cancer Lett. 2007 Apr 18;248(2):269-79. doi: 10.1016/j.canlet.2006.08.004. Epub 
      2006 Sep 22.